The Impact of CAR T-Cell Therapy on Relapsed/Refractory MM Treatment

Opinion
Video

Rahul Banerjee, MD, FACP, discusses how the emergence of CAR T-cell therapy has impacted the multiple myeloma treatment landscape by addressing unmet needs and improving patients’ quality of life.

Video content above is prompted by the following questions:

  • How has the emergence of CAR T-cell therapy impacted the treatment paradigm for relapsed/refractory multiple myeloma?
    • Does this therapy address an unmet need in R/R MM?
    • How do you manage patients who may not meet the eligibility criteria for CAR T-cell therapy but still have a significant unmet need for effective treatment options?
Related Videos
Amrita Y. Krishnan, MD, and Binod Dhakal, MD
Amrita Y. Krishnan, MD, and Binod Dhakal, MD
A panel of 4 experts on multiple myeloma
Video 1 - 4 KOLs are featured in "Triaging and Prioritizing Patients with Multiple Myeloma"
Video 1 - 4 KOLs are featured in "CAR T-Cell Therapy: Leukapheresis Practices"
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Related Content